Weekly Injection Pen

Weight Loss, Reimagined

LIRAVEXIN delivers triple-agonist GLP-1 technology in a once-weekly injection pen—designed for progressive dosing and healthcare-supervised care.

2.5mg

First Dose

1×

Weekly Injection

Learn How It Works For Healthcare Providers Buy Now

Accessories for clinic use

−

Clinical-style transformation visual

Placeholder for before/after photography from your brand kit.

The LIRAVEXIN Advantage

Built around an adjustable weekly pen, progressive dosing, and clinician oversight.

Injection pen preview

◆

Adjustable Dosing Pen

Flexible dosing from starter through maintenance packs (10–25mg range) for personalized titration under clinician guidance.

◆

Progressive Dosing

Clear step-up guide so patients and providers can advance weekly doses safely toward individualized goals.

◆

Flexible Storage

Refrigerate at 36–46°F. After first use, pens may remain at room temperature for up to 21 days per labeling.

◆

Manufactured Quality

Produced under rigorous quality controls for consistent potency and pen reliability.

◆

Easy-to-Use Design

Intuitive grip, dose dial, and clear medication window designed for confident weekly self-administration.

◆

Healthcare Supervised

Prescription only. Treatment decisions and dose changes should be directed by a licensed healthcare provider.

Triple-Agonist Technology

Three complementary metabolic pathways—aligned with the product story on your mockup.

GLP-1 Pathway

Appetite & Glucose Control

Supports satiety signaling and glycemic balance.

GIP Pathway

Metabolic Efficiency

Supports metabolic handling alongside GLP-1.

Glucagon · New Breakthrough

Energy Expenditure

Targets energy expenditure and fat utilization pathways.

How It Works

Dial Your Dose

Select the current week’s prescribed dose on the pen dial.

Choose Injection Site

Abdomen, thigh, or upper arm—rotate sites each week.

Inject Your Dose

Inject at 90° and hold for about 10 seconds.

Adjust & Progress

Follow provider guidelines for step-up dosing.

Important Safety Information

WARNING: Risk of Thyroid C-Cell Tumors

In rodent studies, medicines that act like GLP-1 caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether LIRAVEXIN causes thyroid C-cell tumors, including MTC, in humans. LIRAVEXIN is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients about potential MTC risk and symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and injection-site reactions may occur. Many gastrointestinal effects improve as the body adjusts. Tell your provider about any side effect that bothers you or does not go away.

Report Side Effects: Contact your healthcare provider. You may also report adverse events to FDA MedWatch at 1-800-FDA-1088 or www.fda.gov/medwatch. For product support questions use the contact form below.

Frequently Asked Questions

LIRAVEXIN is a prescription weekly injection pen that uses triple-agonist technology acting on GLP-1, GIP, and glucagon pathways to support weight management under healthcare supervision.

Request Information

Patients and providers can request product information. This is not an emergency service.

Email: info@liravexin.com

Support: 1-800-LIRAVEXIN

For Healthcare ProvidersHCP portal coming soon. Use the form and select “Healthcare Provider”.